Peter Altman, the Chief Executive Officer of BioCardia, has purchased $5,550 worth of common stock in the company. This transaction reflects Altman's continued investment in BioCardia, a firm focused on developing innovative therapies for cardiovascular diseases. The acquisition of shares is part of a broader trend among executives to demonstrate confidence in their company's future performance.
Related Articles
Don't miss out on breaking stories and in-depth articles.